EQL Pharma AB (FRA:7JK) Stock Price, Trades & News

EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.

Financial Strength

4/10

Name	Current	Vs Industry
Cash-To-Debt	0.18
Equity-to-Asset	0.31
Debt-to-Equity	1.82
Debt-to-EBITDA	9.96
Interest Coverage	1.6
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	1.68	Distress Grey Safe
Beneish M-Score	-2.6	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	17.7
	3-Year EBITDA Growth Rate	4.9
	3-Year EPS without NRI Growth Rate	-26.1
	3-Year Book Growth Rate	19.3

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	38.98
	9-Day RSI	40.64
	14-Day RSI	37.94
	3-1 Month Momentum %	-56.32
	6-1 Month Momentum %	-58.06
	12-1 Month Momentum %	-71.91

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.92
	Quick Ratio	0.97
	Cash Ratio	0.41
	Days Inventory	258.71
	Days Sales Outstanding	86.77
	Days Payable	91.52

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-0.5
	Shareholder Yield %	-39.81

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	37.64
	Operating Margin %	11.25
	Net Margin %	2.9
	EBITDA Margin %	11.25
	FCF Margin %	-9.01
	OCF Margin %	6.61
	ROE %	5.02
	ROA %	1.53
	ROIC %	4.97
	3-Year ROIIC %	0.19
	ROC (Joel Greenblatt) %	21.23
	ROCE %	7.86
	Years of Profitability over Past 10-Year	8

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	55.6
	Forward PE Ratio	18.35
	PE Ratio without NRI	55.6
	Shiller PE Ratio	35.61
	PEG Ratio	2.17
	PS Ratio	1.62
	PB Ratio	2.58
	Price-to-Operating-Cash-Flow	24.76
	EV-to-EBIT	22.07
	EV-to-Forward-EBIT	17.02
	EV-to-EBITDA	22.07
	EV-to-Forward-EBITDA	14.86
	EV-to-Revenue	2.48
	EV-to-Forward-Revenue	3.35
	EV-to-FCF	-27.65
	Price-to-DCF (Earnings Based)	4.01
	Price-to-Peter-Lynch-Fair-Value	2.18
	Earnings Yield (Greenblatt) %	4.54
	FCF Yield %	-5.82
	Forward Rate of Return (Yacktman) %	10.22

Financials (Next Earnings Date:2026-08-07 Est.)

Annual Quarterly TTM

FRA:7JK's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

EQL Pharma AB Executives

Details

GF Value™

FRA:7JK

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with 7JK. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	39.669
	EPS (TTM) (€)	0.038
	Beta	-0.2713
	3-Year Sharpe Ratio	0.19
	3-Year Sortino Ratio	0.27
	Volatility %	51.87
	14-Day RSI	37.94
	14-Day ATR (€)	0.072199
	20-Day SMA (€)	2.11415
	12-1 Month Momentum %	-71.91
	52-Week Range (€)	1.968 - 8.8
	Shares Outstanding (Mil)	29.53

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

EQL Pharma AB Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

EQL Pharma AB Stock Events

Financials Calendars

Event	Date	Price (€)
Second quarter earnings results for 2027	2026-11-05	In 113 days
General meeting for 2026	2026-08-21 16:00	In 38 days
First quarter earnings conference call for 2027	2026-08-07 10:00	In 24 days
First quarter earnings results for 2027	2026-08-07	In 23 days
Annual report for 2026	2026-07-28	In 13 days
Fourth quarter earnings results for 2026	2026-05-08	4.47 (-0.45%)
Third quarter earnings results for 2026	2026-02-03	5.96 (+5.30%)
Second quarter earnings results for 2026	2025-11-05	5.56 (-1.42%)
General meeting for 2025	2025-08-21 16:00	7.46 (-1.97%)
First quarter earnings conference call for 2026	2025-08-08 10:00	8.45 (+0.48%)

Show

Entries

EQL Pharma AB Frequently Asked Questions

What is EQL Pharma AB(FRA:7JK)'s stock price today?

The current price of FRA:7JK is €2.05. The 52 week high of FRA:7JK is €8.80 and 52 week low is €1.97.

When is next earnings date of EQL Pharma AB(FRA:7JK)?

The next earnings date of EQL Pharma AB(FRA:7JK) is 2026-08-07 Est..

Does EQL Pharma AB(FRA:7JK) pay dividends? If so, how much?

EQL Pharma AB(FRA:7JK) does not pay dividend.

Press Release

	Subject	Date
No Press Release

Articles on EQL Pharma AB

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.